Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul R Rhomberg

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Diagnostic Microbiology and Infectious Disease|September 12, 2003
Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North AmericaPaul R Rhomberg, Ronald N Jones,
Diagnostic Microbiology and Infectious Disease|May 10, 2005
Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panelsPaul R Rhomberg, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|September 5, 2006
Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005)Paul R Rhomberg, Ronald N Jones
The Journal of Antimicrobial Chemotherapy|December 21, 2002
Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitorRonald N Jones, Paul R Rhomberg
Diagnostic Microbiology and Infectious Disease|February 23, 2002
In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinumPaul R Rhomberg, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|October 17, 2009
Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008)Paul R Rhomberg, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|May 9, 2018
Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare mouldsMichael A Pfaller, Paul R Rhomberg, Mariana Castanheira
Journal of Clinical Microbiology|August 9, 2003
Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinoloneKelley A Gordon, Paul R Rhomberg, Ronald N Jones
Journal of Clinical Microbiology|November 21, 2014
Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinoneRonald N Jones, Nicole M Holliday, Paul R Rhomberg
Diagnostic Microbiology and Infectious Disease|March 11, 2008
Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillanceRonald N Jones, Jeffrey T Kirby, Paul R Rhomberg
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Diagnostic Microbiology and Infectious Disease|September 12, 2003
Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North AmericaPaul R Rhomberg, Ronald N Jones,
Diagnostic Microbiology and Infectious Disease|May 10, 2005
Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panelsPaul R Rhomberg, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|September 5, 2006
Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005)Paul R Rhomberg, Ronald N Jones
The Journal of Antimicrobial Chemotherapy|December 21, 2002
Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitorRonald N Jones, Paul R Rhomberg
Diagnostic Microbiology and Infectious Disease|February 23, 2002
In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinumPaul R Rhomberg, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|October 17, 2009
Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008)Paul R Rhomberg, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|May 9, 2018
Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare mouldsMichael A Pfaller, Paul R Rhomberg, Mariana Castanheira
Journal of Clinical Microbiology|August 9, 2003
Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinoloneKelley A Gordon, Paul R Rhomberg, Ronald N Jones
Journal of Clinical Microbiology|November 21, 2014
Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinoneRonald N Jones, Nicole M Holliday, Paul R Rhomberg
Diagnostic Microbiology and Infectious Disease|March 11, 2008
Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillanceRonald N Jones, Jeffrey T Kirby, Paul R Rhomberg
Pageof 12